TY - JOUR
T1 - Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable
T2 - a retrospective study by the Chronic Malignancies Working Party of the EBMT
AU - McLornan, Donal P
AU - Malpassuti, Vittoria
AU - Lippinkhof-Kozijn, Anne
AU - Potter, Victoria
AU - Beelen, Dietrich
AU - Bunjes, Donald
AU - Sengeloev, Henrik
AU - Radujkovic, Aleksandar
AU - Passweg, Jakob
AU - Chalandon, Yves
AU - Kröger, Nicolaus
AU - Wulf, Gerald G
AU - Johansson, Jan-Erik
AU - Ciceri, Fabio
AU - Bornhäuser, Martin
AU - Holler, Ernst
AU - Guffroy, Blandine
AU - Martin, Sonja
AU - Neubauer, Andreas
AU - Gramatski, Martin
AU - Robin, Marie
AU - Iacobelli, Simona
AU - Hayden, Patrick
AU - Hernández Boluda, Juan C
AU - Czerw, Tomasz
AU - Yakoub-Agha, Ibrahim
N1 - © 2020 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2020/8
Y1 - 2020/8
N2 - Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.
AB - Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.
KW - Adult
KW - Aged
KW - Databases, Factual
KW - Female
KW - Follow-Up Studies
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Incidence
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Mutation
KW - Myeloproliferative Disorders/genetics
KW - Recurrence
KW - Retrospective Studies
KW - Risk
KW - Societies, Scientific
KW - Transplantation Conditioning
KW - Transplantation, Homologous
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1111/bjh.16537
DO - 10.1111/bjh.16537
M3 - Journal article
C2 - 32108327
SN - 0007-1048
VL - 190
SP - 437
EP - 441
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -